New drug improves progression-free survival, shrinks tumors in rare cancer for first time

The experimental drug selumetinib is the first targeted therapy to demonstrate significant clinical benefit for patients with metastatic uveal melanoma, according to new Memorial Sloan-Kettering Cancer Center research presented on Saturday, June 1, at the 49th annual meeting of the American Society of Clinical Oncology.

Fuente : http://www.eurekalert.org/pub_releases/2013-06/msc...